BUSINESS● LOW6d ago · Oct 8, 2026, 5:31 PM
Neurogene is a new Overweight at J.P. Morgan on Rett syndrome therapy
Seeking Alpha Tech · global
J.P. Morgan has initiated coverage on Neurogene with an "Overweight" rating, based on its Rett syndrome therapy. This indicates an analyst's positive outlook on the company's stock, likely due to its medical research and market potential.
GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text.
More in Business
BUSINESSnowMunicipal Securities Underwriters Pay a Total of $325,000 in FinesSECBUSINESSnowSEC CHAIRMAN ARTHUR LEVITT, IOWA OFFICIALS TO HOLD INVESTORS’ TOWN MEETING IN DES MOINESSECBUSINESS24m agoBritish American Tobacco extends 5-day winning streak; RSI flags riskSeeking Alpha TechBUSINESS29m agoBetter Home & Finance stock dips as Q3 revenue is estimated below consensusSeeking Alpha Tech